An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Cyclo Therapeutics to Present at the Virtual Investor 2023 Companies to Watch Event
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Cyclo Therapeutics, Inc. (NASDAQ: CYTH), a clinical-stage biotechnology company, will be presenting at the Virtual Investor 2023 Companies to Watch Event on January 19, 2023, at 11:00 AM ET. CEO N. Scott Fine will lead the presentation, which will be accessible through a live video webcast. Cyclo Therapeutics focuses on developing treatments for diseases, particularly with its orphan drug Trappsol® Cyclo™ aimed at Niemann-Pick Disease Type C and early Alzheimer’s disease.
Positive
None.
Negative
None.
Live video webcast on Thursday, January 19th at 11:00 AM ET
GAINESVILLE, Fla.--(BUSINESS WIRE)--
Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that N. Scott Fine, Chief Executive Officer of Cyclo Therapeutics will present at the Virtual Investor 2023 Companies to Watch Event on Thursday, January 19, 2023 at 11:00 AM ET.
A live video webcast of the presentation will be available on the Events page of the Investors section of the Company’s website (cyclotherapeutics.com). A webcast replay will be available two hours following the live presentation and will be accessible for 90 days.
About Cyclo Therapeutics
Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with disease. The Company’s Trappsol® Cyclo™, an orphan drug designated product in the United States and Europe, is the subject of four formal clinical trials for Niemann-Pick Disease Type C, a rare and fatal genetic disease, (www.ClinicalTrials.govNCT02939547, NCT02912793, NCT03893071 and NCT04860960). The Company is conducting a Phase 2b clinical trial using Trappsol® Cyclo™ intravenously in early Alzheimer’s disease (NCT05607615) based on encouraging data from an Expanded Access program for Alzheimer’s disease (NCT03624842). Additional indications for the active ingredient in Trappsol® Cyclo™ are in development. For additional information, visit the Company’s website: www.cyclotherapeutics.com.
